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Preventive Stenting in Acute Myocardial Infarction 131
Ari Pollack, Bibhu D. Mohanty, Rishi Handa, Patrick M. Looser, Valentin Fuster,
Spencer B. King III, Samin K. SharmaCurrent practice guidelines advocate culprit vessel intervention alone in patients with ST-segment
elevation myocardial infarction (STEMI) found to have multivessel coronary disease during primary
percutaneous coronary intervention. The PRAMI (Preventive Angioplasty in Acute Myocardial
Infarction) trial reinvigorated the debate on the timing of noninfarct artery intervention. In this
review, the authors discuss the pathophysiology of nonculprit vessel plaque in STEMI, provide a
summary of the existing literature on the topic, and discuss the PRAMI trial in the face of previous
data and possible future directions for further study.CLINICAL RESEARCH Increasing Percutaneous Coronary Interventions for ST-Segment Elevation
Myocardial Infarction in the United States: Progress and Opportunity139Rashmee U. Shah, Timothy D. Henry, Stephanie Rutten-Ramos, Ross F. Garberich,
Mourad Tighiouart, C. Noel Bairey MerzHealth care systems emphasize rapid access to percutaneous coronary intervention (PCI) for
ST-segment elevation myocardial infarction (STEMI). The authors used the Nationwide Inpatient
Sample to evaluate the impact of these efforts. Using 2003 as reference, the adjusted odds ratio
(OR) of PCI increased to 4.16 (95% conﬁdence interval [CI]: 3.71 to 4.66) by 2011, and the adjusted
OR of in-hospital death decreased to 0.79 (95% CI: 0.74 to 0.84). After accounting for PCI, the OR
of death was 1.01 in 2011 (95% CI: 0.95 to 1.07) compared with 2003. In summary, the PCI rate
increased from 2003 to 2011, and PCI was a mediator of decreasing STEMI mortality in this
nationally representative sample.CONTINUED ON PAGE A-11
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JANUARY 2015 VOLUME 8, NUMBER 1, PART BDouble-Blind, Randomized, Prospective Comparison of Loading Doses of 600 mg
Clopidogrel Versus 60 mg Prasugrel in Patients With Acute ST-Segment Elevation
Myocardial Infarction Scheduled for Primary Percutaneous Intervention:
The ETAMI Trial (Early Thienopyridine treatment to improve primary PCI in
Patients with Acute Myocardial Infarction)147Uwe Zeymer, Hans-Christian Mochmann, Bernd Mark, Hans-Richard Arntz,
Holger Thiele, Frank Diller, Gilles Montalescot, Ralf ZahnThis double-blind, prospective study randomized 62 patients with ST-segment elevation myocardial
infarction scheduled for primary percutaneous coronary intervention in the ambulance or the
emergency department to 60 mg prasugrel (n ¼ 31) or 600 mg clopidogrel (n ¼ 31). The primary
endpoint platelet reactivity index (PRI) after 2 h (50.4  32.7% vs. 66.3  22.2%; p ¼ 0.035) and
after 4 h (39.1  27.5% vs. 54.5  49.3%; p ¼ 0.038) were signiﬁcantly lower with prasugrel
compared with clopidogrel. In addition, the rate of patients with a PRI <50% tended to be higher
with prasugrel compared with clopidogrel after 2 h (46.7% vs. 28.6%, p ¼ 0.15) and after 4 h
(63.0% vs. 38.9%, p ¼ 0.06).
Prophylactic Warfarin Therapy After Primary Percutaneous Coronary Intervention
for Anterior ST-Segment Elevation Myocardial Infarction155Michel R. Le May, Sudikshya Acharya, George A. Wells, Ian Burwash, Aun Yeong Chong,
Derek Y. So, Chris A. Glover, Michael P.V. Froeschl, Benjamin Hibbert, Jean-François Marquis,
Alexander Dick, Melissa Blondeau, Jordan Bernick, Marino LabinazThis study sought to determine the beneﬁts of adding warfarin therapy to dual-antiplatelet therapy
in patients with apical akinesis or dyskinesis on transthoracic echocardiography after primary
percutaneous coronary intervention (PCI). Of the 460 patients who qualiﬁed, 131 were discharged
on warfarin and 329 without warfarin. Net adverse clinical events (NACE) at 180 days occurred
more frequently in the no warfarin group (14.7% vs. 4.6%, p ¼ 0.001). On propensity score
analysis, warfarin therapy was an independent predictor of NACE (odds ratio: 4.01, 95%
conﬁdence interval: 2.15 to 7.50, p < 0.0001). Our results do not support the addition of warfarin
therapy after primary PCI in patients with apical akinesis or dyskinesis.n EDITORIAL COMMENT
Anticoagulation After Anterior Myocardial Infarction: Primum non Nocere,
or First Do No Harm163Michael C. McDanielCONTINUED ON PAGE A-12
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JANUARY 2015 VOLUME 8, NUMBER 1, PART BRelationship Between Time to Invasive Assessment and Clinical Outcomes of Patients
Undergoing an Early Invasive Strategy After Fibrinolysis for ST-Segment Elevation
Myocardial Infarction: A Patient-Level Analysis of the Randomized Early Routine
Invasive Clinical Trials166Mina Madan, Sigrun Halvorsen, Carlo Di Mario, Mary Tan, Cynthia M. Westerhout,
Warren J. Cantor, Michel R. Le May, Francesco Borgia, Federico Piscione, Bruno Scheller,
Paul W. Armstrong, Francisco Fernandez-Aviles, Pedro L. Sanchez, John J. Graham,
Andrew T. Yan, Shaun G. GoodmanThis study investigated the relationship between time to invasive assessment and clinical outcomes
among ST-segment elevation myocardial infarction patients randomized to a routine early invasive
strategy after ﬁbrinolysis. Early angiography (<4 h) and a shorter symptom onset to angiography
time (<4 h) were not associated with an increased risk of 30-day death or reinfarction or in-
hospital major bleeding and were associated with lower 30-day recurrent ischemia. A shorter
symptom onset to angiography time was associated with reduced 1-year death or reinfarction.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Beyond the Guidelines Stance: Green Light for Very Early Angiography After Fibrinolysis 175
Giuseppe Tarantini
Remote Ischemic Conditioning Reduces Myocardial Infarct Size and Edema in Patients
With ST-Segment Elevation Myocardial Infarction178Steven K. White, Georg M. Frohlich, Daniel M. Sado, Viviana Maestrini, Marianna Fontana,
Thomas A. Treibel, Shana Tehrani, Andrew S. Flett, Pascal Meier, Cono Ariti, John R. Davies,
James C. Moon, Derek M. Yellon, Derek J. HausenloyWhether remote ischemic conditioning (RIC) using transient arm ischemia and reperfusion can reduce
acute myocardial infarct (MI) size, assessed by cardiovascular magnetic resonance (CMR), in
ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention
is unknown. Patients randomly received either RIC (four 5-min cycles of arm cuff inﬂation/
deﬂation) or control (uninﬂated cuff) protocols prior to primary percutaneous coronary
intervention. The authors found that RIC signiﬁcantly reduced MI size on CMR by 27% when
compared with the control protocol. Because RIC also decreased the extent of myocardial edema by
17% (measured by T2-mapping CMR), we were unable to delineate the area at risk and calculate
myocardial salvage.CONTINUED ON PAGE A-13
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JANUARY 2015 VOLUME 8, NUMBER 1, PART BAbsorb Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent in
ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity Score
Matching Comparison: The BVS-EXAMINATION Study (Bioresorbable Vascular
Scaffold-A Clinical Evaluation of Everolimus Eluting Coronary Stents in the
Treatment of Patients With ST-segment Elevation Myocardial Infarction)189Salvatore Brugaletta, Tommaso Gori, Adrian F. Low, Petr Tousek, Eduardo Pinar,
Josep Gomez-Lara, Giancarla Scalone, Eberhard Schulz, Mark Y. Chan, Viktor Kocka,
Jose Hurtado, Juan Antoni Gomez-Hospital, Thomas Münzel, Chi-Hang Lee,
Angel Cequier, Mariano Valdés, Petr Widimsky, Patrick W. Serruys, Manel SabatéRecent studies, limited by lack of a control group and small sample size, have shown short-term
safety and feasibility of bioresorbable vascular scaffold (BVS) implantation in ST-segment
elevation myocardial infarction (STEMI) patients. Our study compared the 1-year outcome of STEMI
patients treated by BVS with propensity-score matched STEMI patients treated either by
everolimus-eluting stent (EES) or by bare-metal stent (BMS). It showed that STEMI patients
treated with BVS had similar rates of device-oriented endpoint compared with those treated with
EES or BMS, although the rate of scaffolds thrombosis, mostly clustered in the early phase, was
not negligible. Larger studies with longer follow-up are needed to conﬁrm our ﬁndings.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Bioresorbable Drug-Eluting Stents: An Immature Technology in Need of
Mature Application198Robert A. Byrne, Adnan Kastrati
Comprehensive Meta-Analysis of Safety and Efﬁcacy of Bivalirudin Versus Heparin
With or Without Routine Glycoprotein IIb/IIIa Inhibitors in Patients With
Acute Coronary Syndrome201Eliano Pio Navarese, Volker Schulze, Felicita Andreotti, Mariusz Kowalewski,
Michalina Kołodziejczak, David E. Kandzari, Tienush Rassaf, Bartosz Gorny,
Maximilian Brockmeyer, Christian Meyer, Sergio Berti, Jacek Kubica, Malte Kelm,
Marco ValgimigliThis meta-analysis compared bivalirudin with heparin with or without a routinely administered
glycoprotein IIb/IIIa inhibitor (GPI) in patients with acute coronary syndrome. Thirteen randomized,
controlled trials were included. There was a reduction of major bleeding with bivalirudin compared
with heparin that was signiﬁcant when heparin was routinely administered with GPI (p < 0.001)
but not with provisionally administered GPI (p ¼ 0.24). Stent thrombosis signiﬁcantly increased
with bivalirudin compared with heparin plus routine GPI use (p ¼ 0.02), but not heparin plus
provisional GPI use (p ¼ 0.42). Bivalirudin in acute coronary syndrome patients is associated with a
reduction of major bleeding compared with heparin with routinely administered GPI, but with an
increase in stent thrombosis rates compared with heparin with or without GPI.
SEE ADDITIONAL CONTENT ONLINECONTINUED ON PAGE A-14
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JANUARY 2015 VOLUME 8, NUMBER 1, PART BAcute Stent Thrombosis After Primary Percutaneous Coronary Intervention: Insights
From the EUROMAX Trial (European Ambulance Acute Coronary Syndrome
Angiography)214Peter Clemmensen, Sebastian Wiberg, Arnoud van’t Hof, Efthymios N. Deliargyris,
Pierre Coste, Jurrien ten Berg, Claudio Cavallini, Martial Hamon, Dariusz Dudek,
Uwe Zeymer, Xavier Tabone, Steen D. Kristensen, Debra Bernstein, Prodromos Anthopoulos,
Jayne Prats, Philippe Gabriel StegThe EUROMAX (European Ambulance Acute Coronary Syndrome Angiography) trial demonstrated a
signiﬁcant decrease in death and major bleeding with bivalirudin compared with heparin with
optional glycoprotein IIb/IIIa inhibitors, but an increase in acute stent thrombosis (AST). This
analysis conﬁrms that the risk for AST is limited to the ﬁrst few hours after primary percutaneous
coronary intervention (PCI) and that neither the new oral P2Y12 inhibitors nor a low-dose
(0.25 mg/kg/h) bivalirudin infusion are protective. However, prolonging the bivalirudin infusion at
the full PCI dose was not associated with a higher risk of AST while maintaining the lower
bleeding rates, suggesting that this strategy could potentially further optimize outcomes in
primary PCI.n EDITORIAL COMMENT
Heparin May Be Hard to Beat: However Much You Are Willing to Spend on Bivalirudin 221
Rod H. StablesVIEWPOINTS Is Heparin an Acceptable Anticoagulant When Glycoprotein IIb/IIIa Inhibitors
Are Not Used?223Michael S. Lee, Seung-Woon Rha, Kyung Woo Park, Moo Hyun Kim
Follow the Data: Bivalirudin (and Not Heparin Alone) During
Percutaneous Coronary Intervention Provides the Best Clinical Outcomes225Gregg W. Stone, Roxana Mehran, Philippe Gabriel StegEDITOR’S PAGE A Focus on ST-Segment Elevation Myocardial Infarction 228
Spencer B. King III
